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Objectives Our aim was to assess the distribution and clinical significance of left ventricular (LV) mass in patients with hy-
pertrophic cardiomyopathy (HCM).
Background Hypertrophic cardiomyopathy is defined echocardiographically by unexplained left ventricular wall thickening.
Left ventricular mass, quantifiable by modern cardiovascular magnetic resonance techniques, has not been sys-
tematically assessed in this disease.
Methods In 264 HCM patients (age 43  18 years; 75% men), LV mass by cardiovascular magnetic resonance was mea-
sured, indexed by body surface area, and compared with that in 606 healthy control subjects.
Results The LV mass index in HCM patients significantly exceeded that of control subjects (104 40 g/m2 vs. 61  10 g/m2
in men and 89  33 g/m2 vs. 47  7 g/m2 in women; both p  0.0001). However, values were within the normal
range (mean 2 SDs for control subjects) in 56 patients (21%), and only mildly increased (mean2 to 3 SDs) in
18 (16%). The LV mass index showed a modest relationship to maximal LV thickness (r2  0.38; p  0.001), and
was greater in men (104  40 g/m2 vs. 89  33 g/m2 in women; p  0.001) and in patients with resting outflow
obstruction (121  43 g/m2 vs. 96  37 g/m2 in nonobstructives; p  0.001). During a 2.6  0.7-year follow-up,
markedly increased LV mass index proved more sensitive in predicting outcome (100%, with 39% specificity),
whereas maximal wall thickness30 mm was more specific (90%, with 41% sensitivity).
Conclusions In distinction to prior perceptions, LV mass index was normal in about 20% of patients with definite HCM pheno-
type. Therefore, increased LV mass is not a requirement for establishing the clinical diagnosis of HCM. The LV
mass correlated weakly with maximal wall thickness, and proved more sensitive in predicting outcome. (J Am
Coll Cardiol 2008;52:559–66) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.047n
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cypertrophic cardiomyopathy (HCM) is the most common
enetic heart disease, characterized by marked clinical and
orphologic heterogeneity (1–3). Diagnosis is usually based
n the echocardiographic finding of unexplained left ven-
ricular (LV) hypertrophy, defined by increased wall thick-
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enter, Boston, Massachusetts; and the Department of Medicine (Cardiovascular
ivision) and Radiology, Beth Israel Deaconess Hospital and Harvard Medical
chool, Boston, Massachusetts. Supported, in part, by grants from the Italian
inistry for Scientific and Technologic Research (PRIN 2006) and the Fondazione
nte Cassa di Risparmio di Firenze, Florence, Italy.t
Manuscript received January 17, 2008; revised manuscript received April 17, 2008,
ccepted April 28, 2008.ess in 1 or more LV segments (2,4). LV mass is generally
ssumed to be increased in patients with phenotypically
xpressed HCM, based largely on early pathological studies
5,6). However, in vivo assessment of LV mass by echocar-
iography has been judged unreliable in HCM, due to the
symmetric distribution of hypertrophy and heterogeneous
hamber morphology (4). Therefore, the distribution and
linical correlates of LV mass have not been previously
ssessed in this disease.
See page 567
Cardiovascular magnetic resonance (CMR), by virtue of its
igh-resolution volumetric reconstruction of the LV chamber,
urrently affords a highly accurate and reproducible quantita-
ive assessment of mass (7,8). In the present cross-sectional
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Assessment of CMR LV Mass in HCM August 12, 2008:559–66study, we sought to examine
whether CMR contributes to our
understanding of the morphology
and clinical correlates of the HCM
phenotype, with respect to echo-
cardiographic measures, in a large
multicenter cohort.
Methods
Study population. HCM PA-
TIENTS. The study population
comprised 264 patients with
CM (age 43  18 years; 75% men, body surface area
BSA] 2.0  0.3 m2 for men and 1.7  0.2 m2 for women)
onsecutively referred for CMR at 4 participating institu-
ions: Minneapolis Heart Institute Foundation, Minneap-
lis, Minnesota (n  95); Azienda Ospedaliera Careggi,
lorence, Italy (n  80); Tufts-New England Medical
enter, Boston, Massachusetts (n  49); and Ospedale S.
ndrea, Rome, Italy (n  40) (Table 1). All HCM patients
ere probands, had an expressed phenotype permitting an
nequivocal clinical diagnosis (2), and were referred specif-
cally for disease evaluation; family members identified
olely by virtue of pedigree studies were not included.
Diagnosis of HCM was based on 2-dimensional echocar-
iographic evidence of a hypertrophied, nondilated LV (max-
mal wall thickness15 mm, or the equivalent relative to BSA
n children), in the absence of another cardiac or systemic
isease that could produce the magnitude of hypertrophy
vident (1,2). CMR examinations were performed in all
atients within 2 weeks of echocardiography. The study
rotocol was approved by the respective internal review board
r research ethics committees of each institution, and written
nform consent was obtained from each subject.
ONTROL SUBJECTS. A total of 606 healthy adult participants
n the Framingham Heart study (239 men; 367 women)
ithout systemic hypertension or evidence of cardiovascular
isease were studied by CMR, using a scanning protocol
imilar to that reported here for patients with HCM (8). Mean
ge was 61  8 years for both men and women. BSA was 2.0
0.2 m2 for men and 1.7  0.2 m2 for women.
chocardiography. Echocardiographic studies were per-
ormed with commercially available instruments. LV hyper-
rophy was assessed with 2-dimensional echocardiography,
nd the site and extent of maximal wall thickness were
dentified (4). Maximal end-diastolic LV wall thickness was
aken as the dimension of greatest magnitude at any site
ithin the LV chamber (4). Peak instantaneous LV outflow
radient was estimated with continuous wave Doppler
nder basal conditions (9). LV outflow obstruction, due to
itral valve systolic anterior motion and mitral-septal con-
act, was identified by a peak instantaneous outflow gradient
30 mm Hg (9).
MR. All CMR examinations were performed using com-
Abbreviations
and Acronyms
BSA  body surface area
CMR  cardiovascular
magnetic resonance
HCM  hypertrophic
cardiomyopathy
LV  left
ventricle/ventricular
OR  odds ratioercially available scanners (Philips ACS-NT 1.5 T byroscan-Intera, Best, the Netherlands or Siemens Sonata
.5 T, Erlangen, Germany) and a commercial cardiac coil.
lectrocardiographic-gated, steady-state, free precession
reath-hold cines in sequential 10-mm short-axis slices (no
ap) were acquired starting parallel to the atrioventricular
ing and covering the entire ventricle. LV end-diastolic and
nd-systolic volumes, LV mass, and wall thickness were
alculated with commercially available work-stations (Easy
ision 5.0, and View Forum, Philips Medical System, Best,
he Netherlands; or Argus, Siemens, Erlangen, Germany).
ost-processing and analysis of LV volumes and mass were
erformed according to criteria previously agreed upon by
nvestigators from each center.
For the calculation of LV mass, the endocardial and
picardial borders of the LV myocardium were manually
lanimetered on successive short-axis cine images at end-
iastole. The most basal slice at end-diastole was visually
nspected, and, if ventricular myocardium was present, it
as planimetered and included in the mass calculation. If
yocardium but no intracavitary blood pool was present on
he most apical slice, it was included in the mass calculation
y planimetering only the epicardial border. Particular care
as taken to avoid including papillary muscles in the LV
ass calculation. The LV mass was derived by the summa-
ion of discs method and multiplying myocardial muscle
olume by 1.05 g/cm3 (10,11). The LV mass was indexed to
SA. Maximum end-diastolic LV wall thickness was taken
s the dimension of greatest magnitude at any site within
he LV wall. The CMR measurements were performed by
n experienced investigator at each center, blinded to the
esults of echocardiography.
Finally, the presence of delayed enhancement was as-
essed by visual inspection 15 min after intravenous admin-
stration of 0.2 mmol/kg gadolinium-diethylenetriamine
enta-acetic acid (Magnevist, Schering, Berlin, Germany)
ith a breath-held segmented inversion-recovery sequence
inversion time 240 to 300 ms), which was acquired in the
ame views as the cine images (7).
tatistical methods. Data were expressed as mean  SD.
or the comparison of 2 and more than 2 normally
istributed variables, we employed the Student t test and
-way analysis of variance (ANOVA) followed by Bonfer-
oni’s post-hoc test, respectively. The chi-square test was
tilized to compare noncontinuous variables expressed as
roportions; however, the Fisher exact test was employed
hen 1 or more cells in the comparison table had an
xpected frequency of 5. Intraobserver and interobserver
ariability for CMR measurement of LV mass index were
ssessed in 100 randomly selected patients, using Pearson’s
orrelation method.
Independent predictors of normal LV mass index were
ssessed by stepwise (forward conditional) multivariate lo-
istic regression analysis. The relationship between echo-
ardiographic and CMR-derived LV wall thickness values
as assessed by linear regression analysis. The relationship
etween LV wall thickness and mass values was assessed by
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August 12, 2008:559–66 Assessment of CMR LV Mass in HCMegression analysis using a cubic model, to account for the
omparison of a linear with tridimensional (volumetric)
ariable. The survival curve was constructed according to the
aplan-Meier method. All p values are 2-sided and con-
idered significant when 0.05. Calculations were per-
ormed with SPSS 12.0 software (SPSS Inc., Chicago,
linical Features in 264 Patients With HCM and CMR
Table 1 Clinical Features in 264 Patients With HCM and CMR
Overall
N
(Male
Female
No. of patients 264 5
Male 197 (75%) 4
Age at study entry (yrs) 43 18 (8–86) 4
Age at diagnosis (yrs) 38 18 3
Body surface area (m2) 1.9 0.3 1
Family history of HCM-related sudden death 39 (15%) 1
NYHA functional class 1.5 0.7 1
I 159 (60%) 3
II 83 (31%) 1
III/IV 22 (9%)
Angina 67 (25%) 1
End-stage (ejection fraction 50%) 8 (3%)
Medical treatment 176 (67%) 3
Beta-blockers 144 (54%) 2
Verapamil 41 (15%)
Amiodarone 14 (5%)
Disopyramide 8 (3%)
Diabetes mellitus 10 (4%)
Systemic hypertension 54 (20%)
Echocardiography
Left atrium (mm) 43 8 4
Maximal LV wall thickness (mm) 21 6 1
Maximal LV thickness 30 mm 29 (11%)
LV end-diastolic dimension (mm) 45 6 4
LV end-systolic dimension (mm) 26 6 2
LV outflow obstruction at rest (30 mm Hg) 47 (18%)
LV end-diastolic volume (ml) 105 35 11
LV end-systolic volume (ml) 37 11 4
Ejection fraction (%) 65 8 6
Moderate-to-severe mitral regurgitation 11 (4%)
CMR
Maximal LV wall thickness 21 6 1
Maximal LV thickness 30 mm 26 (10%)
LV mass (g) 193 84 13
LV mass index (g/m2) 101 39 6
LV end-diastolic volume (ml) 135 44 12
LV end-diastolic volume index (ml/m2) 70 18 6
LV end-systolic volume (ml) 40 21 3
LV end-systolic volume index (ml/m) 21 10 2
Ejection fraction (%) 71 10 7
LV mass/volume ratio 1.5 0.7 1
Post-contrast delayed enhancement 169 (64%) 2
Normal left ventricular (LV) mass index is defined as mean 2 SD in normal control group (acc
ncreased is defined as mean 3 SD; †p  0.05 versus each of the other 2 groups by chi-square
f variance.
CMR  cardiovascular magnetic resonance; HCM  hypertrophic cardiomyopathy; N/A  not allinois). esults
ssessment of LV mass. CONTROL SUBJECTS. LV mass
ndexed to BSA was 53  8 g/m2, and was significantly
reater in men than women (61 10 g/m2 vs. 47 7 g/m2,
espectively, p  0.001). The upper limit of normal (mean
LV Mass Index (g/m2)*
p Value
l*
g/m2 ;
g/m2)
Mildly Increased
(Males 81–91 g/m2 ;
Females 62–69 g/m2)
Markedly Increased
(Males >91 g/m2 ;
Females >69 g/m2)
) 41 (16%) 167 (63%)
)† 31 (74%) 117 (70%) 0.04
9 45 19 43 18 0.57
8 40 18 38 19 0.74
.3 2.0 0.2 1.9 0.3 0.43
) 6 (14%) 22 (13%) 0.49
.6 1.5 0.6 1.5 0.7 0.36
) 22 (52%) 100 (60%)
) 17 (41%) 49 (30%)
3 (7%) 17 (10%)
) 9 (21%) 44 (27%) 0.79
0 7 (4%) 0.16
) 32 (76%) 111 (68%) 0.19
) 23 (55%) 92 (56%) 0.87
) 7 (17%) 28 (17%) 0.53
5 (12%) 7 (4%) 0.11
1 (2%) 5 (3%) 0.94
2 (5%) 8 (5%) 0.58
) 11 (27%) 34 (20%) 0.57
§ 45 8 44 8 0.03
19 4 23 6 0.001
1 (2%) 25 (15%) 0.02
44 5 45 7 0.49
26 6 26 7 0.69
†‡ 9 (21%) 37 (22%) 0.002
9 101 33 96 37 0.18
4 36 12 34 11 0.62
64 7 65 9 0.52
1 (2%) 8 (5%) 0.25
‡ 21 5 23 6 0.001
2 (5%) 22 (13%) 0.036
0 159 34 222 91 N/A
1 81 10 118 40 N/A
0 131 45 138 46 0.21
6 66 16 73 19† 0.005
8 36 17 41 23 0.25
18 7 22 11 0.09
73 8 70 10 0.35
.3 1.3 0.3 1.7 0.7§ 0.001
) 24 (57%) 116 (70%)§ 0.031
to gender), mildly increased is defined as between mean 2 SD and mean 3 SD, and markedly
er exact test (‡); §p  0.05 versus the other 2 groups by Bonferroni’s post-hoc test after analysis
le; NYHA  New York Heart Association.orma
s <81
s <62
6 (21%
9 (87%
1 1
7 1
.9 0
1 (20%
.4 0
7 (66%
7 (30%
2 (4%)
4 (25%
1 (2%)
3 (59%
9 (52%
6 (11%
2 (4%)
2 (4%)
0 (0%)
9 (16%
1 8
8 4
3 (5%)
6 5
7 6
1 (2%)
2 2
0 1
4 8
2 (4%)
8 5
2 (4%)
3 3
8 1
7 4
5 1
8 1
0 9
0 9
.1 0
9 (52%
ording
or Fish2 SDs) was 81 g/m2 for men and 61 g/m2 for women.
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Assessment of CMR LV Mass in HCM August 12, 2008:559–66CM PATIENTS. LV mass index was 100  39 g/m2, and
as significantly greater in men than women (104  40
/m2 vs. 89  33 g/m2, respectively; p  0.001) (Fig. 1,
able 2), despite identical maximal echocardiographic LV
all thickness (21  6 mm vs. 21  5 mm; p  0.65), and
as similar among the 4 participating centers (Florence, 104
0 g/m2; Boston, 102  28 g/m2; Minneapolis, 99  39
/m2; Rome, 96  27 g/m2; overall ANOVA p value 
.69). Intraobserver and interobserver reproducibility was
igh; the average difference in LV mass index was 5  7
/m2 and 7  9 g/m2, respectively; the Pearson correlation
oefficient was 0.967 and 0.959, respectively (p  0.001 for
oth).
The LV mass index in HCM patients markedly exceeded
hat of normal control subjects (p  0.0001 for both
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Figure 1 Distribution of LV Mass Index
in the 264 Study Patients With HCM
The bars represent the percentage of patients in each subgroup
according to gender. HCM  hypertrophic cardiomyopathy; LV  left ventricular.
MR Findings Accordingo Gender in 264 HCM Patients
Table 2 CMR Findings Accordingto Gender in 264 HCM Patients
Men Women p Value
n 197 67
Age at enrollment (yrs) 42 18 47 19 0.09
Body surface area (m2) 2.0 0.3 1.7 0.2 0.001
Maximal LV wall thickness 22 3 21 5 0.69
Maximal LV thickness30 mm 21 (11%) 5 (8%) 0.63
LV mass (g) 207 81 152 60 0.001
LV mass index (g/m2) 104 40 89 32 0.009
LV end-diastolic volume (ml) 143 45 111 31 0.001
LV end-diastolic volume index (ml/m2) 72 19 66 15 0.007
LV end-systolic volume (ml) 42 22 32 18 0.001
LV end-systolic volume index (ml/m) 21 10 19 11 0.15
Ejection fraction (%) 70 10 72 10 0.34
LV mass/volume ratio 1.5 0.7 1.4 0.5 0.06
Post-contrast delayed enhancement 128 (65%) 41 (61%) 0.65
omparison of normally distributed variables by Student t test; comparison of noncontinuous
ariables expressed as proportions by chi-square.
Abbreviations as in Table 1.enders). However, 56 (21%) HCM patients (49 men; 7
omen) had CMR LV mass values within 2 SDs from the
ean of the control group (i.e.,95th percentile for normal
ndividuals) (Fig. 2), and were regarded as within the
ormal range. An additional 42 (16%) HCM patients (31
en; 11 women) showed only mildly increased LV mass
i.e., were 2 to 3 SDs from the mean for the control group
r 95th to 99th percentile for normal individuals). The
emaining 167 (63%; 117 men and 50 women) had mark-
dly increased LV mass index (Fig. 2, Table 1).
linical correlates of LV mass. Independent predictors of
ormal LV mass index at multivariate analysis were male
ender (odds ratio [OR] vs. women: 4.3; p  0.008), lesser
aximal LV wall thickness (OR per mm increment: 0.79; p
.001), smaller end-diastolic volume (OR per ml increment:
.98; p  0.001) and absence of outflow obstruction at rest
OR vs. obstructive patients: 10.9; p  0.02).
LV mass index was greater in obstructive than in nonob-
tructive patients (121  43 g/m2 vs. 96  37 g/m2,
espectively; p  0.001), despite similar maximal LV
hickness (23  7 mm vs. 21  6 mm, respectively; p 
.06). Only 1 (2%) of 47 patients with a resting outflow
ract gradient 30 mm Hg had a normal LV mass index
Figure 2 Distribution of LV Mass Index According to Gender
Mean left ventricular (LV) mass index 2 SD (solid lines) and 3 SD (dashed
lines) of the reference control population are reported. The LV mass in hyper-
trophic cardiomyopathy patients was defined as normal when 2 SD, mildly
increased when within 2 to 3 SD, and markedly increased when 3 SD of con-
trol subjects. Higher reference values in male subjects account for the greater
number of male patients with normal LV mass index compared with female
patients.
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August 12, 2008:559–66 Assessment of CMR LV Mass in HCMompared with 55 (25%) of 217 patients without obstruc-
ion (p  0.001). In addition, patients with markedly
ncreased LV mass showed a greater prevalence of delayed
nhancement as compared with patients from the other 2
roups (Table 1).
Conversely, LV mass index was unrelated to age (103 
7 g/m2, 98 29 g/m2, and 101 35 g/m2, among patients
40, 40 to 60, and60 years of age, respectively; ANOVA
 0.67), or severity of heart failure symptoms (98  31
/m2, 104  51 g/m2, and 105  44 g/m2 for patients in
ew York Heart Association functional classes I, II, and
Figure 3 Comparison of Different Techniques
to Assess Maximum LV Wall Thickness
Scatterplot illustrating the linear relationship between maximal left ventricular
(LV) wall thickness measured by echocardiography (echo) and by cardiovascular
magnetic resonance (CMR) in 264 hypertrophic cardiomyopathy patients.
Figure 4 Individual LV Mass Variability in Patients With HCM
Cardiovascular magnetic resonance 4-chamber end-diastolic images from 2 HCM p
septum), but markedly different LV mass index values (A  184 g/m2; B  92 g/
ness beyond the ventricular septum and into the LV free wall in A, while the patien
RV  right ventricular cavity; VS  ventricular septum; other abbreviations as in FII/IV, respectively; ANOVA p 0.42). Seven of 8 patients
ith end-stage progression (ejection fraction 50%) had
ncreased LV mass index (up to 283 g/m2); as a group,
owever, end-stage patients did not differ significantly from
hose with preserved LV systolic function (125  77 g/m2
s. 99  38 g/m2, respectively; p  0.11).
aximum LV wall thickness. ECHOCARDIOGRAPHY. Maxi-
al LV wall thickness in HCM patients was 21  6 mm
range 13 to 45 mm), including 29 individuals 30 mm
11%). The location of maximal wall thickness was the
entricular septum in 230 patients (87%), anterolateral free
all in 25 (9%), and apex in 9 (4%).
MR. Maximal LV wall thickness was 21  6 mm (range
3 to 45 mm), closely related to that measured by echocar-
iography (r2  0.70, p  0.0001; average difference in
ndividual patients 0.3  3.4 mm) (Fig. 3), and included 26
atients (9%) with a thickness 30 mm. Also, similar to
chocardiography, CMR identified predominant LV wall
hickness in the septum of 230 patients (87%), anterolateral
ree wall in 25 (9%), and apex in 9 (4%).
Maximal LV wall thickness by echocardiography ex-
eeded CMR by 2 mm in 88 patients (33%; range 2 to 8
m). Maximal CMR wall thickness exceeded that with
chocardiography by2 mm in 71 patients (27%; range 2 to
mm). In the remaining 105 patients (40%), differences
etween the 2 techniques were negligible (1 mm).
ELATION TO LV MASS. A cubic relationship was present
etween maximal LV wall thickness by echocardiography
nd CMR LV mass index (r2  0.38, p  0.001). Despite
chieving statistical significance, this relationship was mod-
st, due to the substantial variability of mass values with
espect to individual LV thicknesses (Fig. 4). For example,
5 patients with an identical echocardiographic LV wall
hickness of 21 mm showed LV mass index that ranged
idely from 64 to 220 g/m2, including 3 within normal
s with identical maximal LV wall thickness (i.e., 33 mm in the anterior ventricular
he difference in mass is due to the extensive distribution of increased LV thick-
shows hypertrophy confined to the septum. FW  free left ventricular wall;
.atient
m2). T
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Assessment of CMR LV Mass in HCM August 12, 2008:559–66imits, 1 with mildly increased, and 11 with markedly
ncreased mass.
As a group, the 29 patients with extreme LV wall thickness
y echocardiography (30 mm) showed a marked increase in
V mass index (145  62 g/m2). However, the range was
onsiderable (43 to 329 g/m2) and included 3 male patients
ith relatively localized LV hypertrophy and normal LV mass
alues (i.e., 43, 68, and 78 g/m2) (Fig. 4).
utcome. Over a 2.6  0.7-year follow-up, there were 10
CM-related deaths: 5 sudden death events (including 1
esuscitated cardiac arrest and 2 appropriate implantable
ardioverter-defibrillator discharges), 3 due to heart failure,
nd 2 after surgical septal myectomy. Patients who died of
CM had significantly greater LV mass index than survi-
ors (128  62 g/m2 vs. 99  38 g/m2; p  0.02). All 10
CM patients who died were in the subgroup of 167
atients with markedly increased LV mass index (6%), while
o events occurred among the 97 patients with normal or
ildly increased LV mass (Kaplan-Meier survival analy-
is p  0.019) (Fig. 5).
Conversely, 4 HCM-related deaths occurred among the
9 patients with echocardiographic maximal LV thick-
ess 30 mm (14%), compared with 6 (of which 4 were
udden) among the 235 patients 30 mm (Kaplan-Meier
urvival analysis p  0.016). As a result, a markedly
ncreased LV mass (91 g/m in men and 69 g/m in
omen) index proved to be more sensitive with regard to
CM-related death (100%, with 39% specificity),
hereas a maximal wall thickness 30 mm was more
pecific (90%, with 41% sensitivity).
iscussion
n this large multicenter cohort of 264 patients presenting
ith an echocardiographic phenotype diagnostic of HCM,
p=0.019
100
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70
60
50
0 1 2 3 4
Normal / 
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of
 H
C
M
-R
el
at
ed
 D
ea
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%
)
Follow-Up after CMR (Years)
Markedly Increased
LV Mass Index: 
Figure 5 LV Mass and Outcome
Kaplan-Meier curve showing the cumulative survival free from cardiovascular mor-
tality with respect to LV mass index. CMR  cardiovascular magnetic resonance;
other abbreviations as in Figure 1.fiMR has added new perspectives to the morphologic
xpression of the disease. Based on early necropsy studies,
CM has been generally regarded as a condition charac-
erized by greatly increased cardiac mass (5,6). With the
ntroduction of echocardiography, increased LV wall thick-
ess became the sine qua non of the HCM phenotype, and
he large heterogeneity of the extent and distribution of
ypertrophy became evident (1–4). By inference, these
ndings suggested a broad spectrum of LV mass in this
isease (4). Nevertheless, quantitative assessment of mass
ith 2-dimensional echocardiography has been generally
egarded as unreliable in HCM, due largely to nontomo-
raphic cross-sectional planes, as well as the heterogeneous
eometry of the LV chamber (4). By providing high-
esolution volumetric reconstruction of the LV (7,8,10),
MR is superior to 2-dimensional echocardiography for
uantitative assessment of LV mass (12), and consequently
ffers a unique opportunity to revisit and characterize more
efinitively the phenotypic expression of HCM in vivo. To
his purpose, we have prospectively assembled a large cohort
f HCM patients studied with both CMR and echocardi-
graphy, to clarify the extent to which this genetic disease
ncreases LV mass, and the interaction of mass and wall
hickness.
First, in distinction to prior perception, we found that an
ncreased LV mass is not invariably present in patients with
CM, and therefore cannot be considered a requirement to
stablish this clinical diagnosis. When compared with600
ealthy adult participants in the Framingham Heart study,
erving as normal control subjects, over 20% of our study
atients from hospital-based cohorts had CMR-calculated
V mass index values that fell within the normal range (i.e.,
95th percentile of normal subjects), and another 16% had
nly mildly increased mass (95th to 99th percentile of
ormal subjects). In systematic HCM pedigree analyses,
ffected individuals frequently exhibit mild phenotypes,
hich may be associated with normal LV mass (13–16).
onsequently, it is reasonable to speculate that in the
eneral HCM population (i.e., including referred and non-
eferred patients), the proportion of patients with normal
V mass may substantially exceed the 20% reported here
16). These observations underscore the novel principle that
V mass may not be augmented in HCM, and defines a
eretofore unrecognized subset of patients with normal LV
ass (13–17). Of note, prior studies employing CMR in
CM patients were often based on selected cohorts of
imited size, predominantly comprised of patients with
evere disease expression and obstruction to LV outflow
18,19). This selection bias probably accounts for the higher
V mass values reported in those studies, compared with
hose in our present patient group.
Second, LV mass was distinctively increased in specific
ubgroups of HCM patients. Specifically, LV mass index
as substantially greater in male than female patients. This
nding differs from echocardiographic measurements of
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August 12, 2008:559–66 Assessment of CMR LV Mass in HCMaximal wall thickness (as an estimate of LV hypertrophy),
eporting little difference between the genders (9,20–26).
oreover, LV mass index was greater in patients with LV
utflow obstruction at rest, probably the result of the
ncreased intraventricular systolic pressure load (18,19),
espite a comparable magnitude of LV wall thickness
etween the obstructive and nonobstructive patients. This
bservation supports the hypothesis of secondary hypertro-
hy in HCM caused by impedance to LV outflow, and also
ontrasts sharply with prior echocardiographic studies
9,18,19,22,23).
Third, maximal LV wall thickness often proved to be an
nreliable estimate of total LV mass index, despite a
tatistically significant relationship between these 2 param-
ters. For example, HCM patients with an echocardio-
raphic wall thickness of 21 mm (the mean in this cohort,
imilar to that of other HCM populations) (9,22–25)
howed adjusted mass values that ranged from normal (64
/m2) to greatly increased (220 g/m2). In addition, a
onsiderable proportion of patients with extreme LV wall
hickness (30 mm) (25,27,28) did not show a marked
ncrease in LV mass, and 3 of these patients were actually
ithin the normal range. Such mismatches between abso-
ute LV wall thickness and mass reflect the heterogeneity of
he HCM phenotype, due primarily to the variable distri-
ution of hypertrophy in regions of the LV chamber remote
rom the site of maximal thickness (4).
This latter observation raises potentially important man-
gement considerations. Current risk stratification strategies
or young HCM patients have used extreme LV wall
hickness (30 mm) to represent the overall burden of
ypertrophy (23–25). However, the present analysis sug-
ests that calculated LV mass could prove more relevant to
he assessment of risk in HCM. Over the available follow-
p, markedly increased LV mass index by CMR was
ssociated with HCM-related mortality with greater sensi-
ivity (although lower specificity) than maximal LV thick-
ess. Nevertheless, revising risk stratification guidelines in
CM, currently based on echocardiography (2,3), in accord
ith calculated LV mass, will require new prospective
MR-driven studies with long periods of observation,
hich are well beyond the scope of the present investigation.
onclusions
he LV mass index was normal in a substantial subset of
atients with HCM. Therefore, normal LV mass does not
xclude the diagnosis of HCM in the presence of increased
egmental wall thickness. Left ventricular mass correlated
eakly with maximal wall thickness, and proved more
ensitive in predicting HCM-related mortality. In this
omplex and heterogeneous disease, CMR affords the op-
ortunity to achieve enhanced phenotypic characterization
nd, possibly, to improve risk stratification.eprint requests and correspondence: Dr. Iacopo Olivotto,
entro di Riferimento per le Cardiomiopatie, Cardiologia San
uca, Azienda Ospedaliera Universitaria Careggi, Viale Pieraccini
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